These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A non-viral gene therapy for treatment of recessive dystrophic epidermolysis bullosa. Cutlar L; Zhou D; Hu X; Duarte B; Greiser U; Larcher F; Wang W Exp Dermatol; 2016 Oct; 25(10):818-20. PubMed ID: 27117059 [No Abstract] [Full Text] [Related]
7. EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa. Gaucher S; Lwin SM; Titeux M; Abdul-Wahab A; Pironon N; Izmiryan A; Miskinyte S; Ganier C; Duchatelet S; Mellerio JE; Bourrat E; McGrath JA; Hovnanian A Br J Dermatol; 2020 Mar; 182(3):794-797. PubMed ID: 31557321 [No Abstract] [Full Text] [Related]
8. Gene therapy for recessive dystrophic epidermolysis bullosa. Titeux M; Pendaries V; Hovnanian A Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504 [TBL] [Abstract][Full Text] [Related]
9. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108 [TBL] [Abstract][Full Text] [Related]
10. The Coming of Age of Topical Gene Therapy for Dystrophic Epidermolysis Bullosa. Schaffer DV N Engl J Med; 2022 Dec; 387(24):2279-2280. PubMed ID: 36516094 [No Abstract] [Full Text] [Related]
11. Cutaneous verrucous xanthoma in a bone marrow transplant recipient with recessive dystrophic epidermolysis bullosa. Boyd AS; Roffwarg D Pediatr Dermatol; 2013; 30(4):480-3. PubMed ID: 23600757 [TBL] [Abstract][Full Text] [Related]
12. Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutations. von Bartenwerffer W; Has C; Arin MJ; Tantcheva-Poór I; Kreuter A; Kremer K; Arshah T; Hoffmann M; Eming SA; Kohlhase J; Krieg T; Bruckner-Tuderman L; Hartmann K Eur J Dermatol; 2011; 21(2):170-2. PubMed ID: 21382783 [TBL] [Abstract][Full Text] [Related]
14. Treatment of hereditary epidermolysis bullosa: updates and future prospects. Hsu CK; Wang SP; Lee JY; McGrath JA Am J Clin Dermatol; 2014 Feb; 15(1):1-6. PubMed ID: 24402870 [TBL] [Abstract][Full Text] [Related]
15. [Recessive dystrophic bullous epidermolysis: Is the etiological treatment at the streetcorner?]. Dereure O Ann Dermatol Venereol; 2011 Oct; 138(10):710-1. PubMed ID: 21978513 [No Abstract] [Full Text] [Related]
16. Dystrophic forms of epidermolysis bullosa. Uitto J; Christiano AM Semin Dermatol; 1993 Sep; 12(3):191-201. PubMed ID: 8217558 [TBL] [Abstract][Full Text] [Related]
17. Skin expression of metalloproteinases and tissue inhibitor of metalloproteinases in sibling patients with recessive dystrophic epidermolysis and intrafamilial phenotypic variation. Bodemer C; Tchen SI; Ghomrasseni S; Séguier S; Gaultier F; Fraitag S; de Prost Y; Godeau G J Invest Dermatol; 2003 Aug; 121(2):273-9. PubMed ID: 12880418 [TBL] [Abstract][Full Text] [Related]
18. "Sporadic" dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation? Vaccaro M; Moretti G; Guarneri F; Cannavò S; Magaudda L Eur J Dermatol; 2000 Aug; 10(6):436-8. PubMed ID: 10980463 [TBL] [Abstract][Full Text] [Related]
19. Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper. Doolan BJ; McGrath JA; Mellerio JE Br J Dermatol; 2024 Feb; 190(3):340-342. PubMed ID: 37936299 [No Abstract] [Full Text] [Related]